KMBC: Clinical Trial at Saint Luke's Cancer Institute Shows Promising Results for New Breast Cancer Drug

HER2-positive breast cancer impacts 20-30 percent of all breast cancer patients. This form of breast cancer tends to be more aggressive and impact younger women. 

A recent clinical trial has shown promising results and may offer another treatment option for these patients. Phase 3 of the SOPHIA study looked at the impact of a new drug called Margetuximab.

KMBC talked to Dr. Tim Pluard, the medical director of Saint Luke's Cancer Institute, about the study's results locally.

Watch the full video below.

Related Content

Mar. 26, 2019

FOX4: Clinical Trial for New Breast Cancer Drug Shows Positive Results

A recent study of a new drug for HER2 breast cancer has shown promising results. FOX4 talked to Dr. Tim Pluard about what this means for breast cancer patients.
Mar. 18, 2019

KCTV: Saint Luke's High-Risk Breast Clinic

Saint Luke's High-Risk Breast Clinic allows women with a higher chance of developing breast cancer to be closely monitored. Dr. Ruby Meierotto shared tips for reducing your risk on Better Kansas City.
Mar. 19, 2019

KSHB: Doctors Say 3D Mammograms Help Catch Cancer Early

One in eight women in the U.S. will develop breast cancer in their lifetime. KSHB talked to Dr. Kelsey Flynt about how early detection is key and how 3D mammograms are helping.